Drugs / CD19/BAFF-R in vivo CAR-T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07383233 | Jun 2026 → May 2028 expected | acute leukemia, lymphoma | Qi deng | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/BAFF-R in vivo CAR-T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07383233 ↗ |
| Modality | Cell therapy | “CD19/BAFF-R in vivo CAR-T cell therapy” NCT07383233 ↗ |